For the quarter ending 2026-03-31, ANIP made $237,462K in revenue. $29,492K in net income. Net profit margin of 12.42%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues | 237,462 | 224,592* | 227,813 | 211,371 |
| Cost of sales (excluding depreciation and amortization) | 93,582 | 90,897* | 93,389 | 74,615 |
| Research and development | 10,600 | 8,406* | 12,304 | 16,535 |
| Gain on sale of building | - | - | - | 0 |
| Selling, general, and administrative | 73,655 | 80,105* | 76,656 | 81,771 |
| Depreciation and amortization | 20,919 | 22,548* | 22,632 | 23,281 |
| Contingent consideration fair value adjustment | -182 | -11,222* | -14,470 | 1,277 |
| Gain (loss) on disposal of assets | - | 503* | -295 | - |
| Restructuring activities | - | 0* | - | - |
| Intangible asset impairment charge | - | -1,534* | 767 | - |
| Total operating expenses, net | 198,574 | 188,695* | 191,573 | 197,479 |
| Operating income | 38,888 | 35,897* | 36,240 | 13,892 |
| Unrealized loss (gain) on investment in equity securities | 5,753 | -2,384* | 3,140 | 332 |
| Interest expense, net | -3,769 | -4,812* | -4,727 | -5,438 |
| Other (expense) income, net | -651 | 605* | -853 | 1,739 |
| Loss on extinguishment of debt | - | 0* | 0 | - |
| Income before income tax expense | 40,221 | 29,305* | 33,800 | 10,525 |
| Income tax expense | 10,729 | 3,716* | 7,183 | 1,976 |
| Net income | 29,492 | 25,589* | 26,617 | 8,549 |
| Dividends on series a convertible preferred stock | 0 | 31* | 344 | 407 |
| Net income available to common shareholders | 29,492 | 25,558 | 26,273 | 8,142 |
| Basic EPS | 1.31 | 1.262 | 1.19 | 0.37 |
| Diluted EPS | 1.28 | 1.147 | 1.13 | 0.36 |
| Basic Average Shares | 20,914,000 | 20,251,000 | 20,074,000 | 19,834,000 |
| Diluted Average Shares | 21,544,000 | 22,283,000 | 21,093,000 | 20,308,000 |
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)